Therapeutic AIDS Vaccines

Bourinbaiar, Aldar S.; Root‐Bernstein, Robert; Abulafia-Lapid, Rivka; Rytik, P. G.; Kanev, A. N.; Jirathitikal, Vichai; Orlovsky, V. G.

doi:10.2174/138161206777442119

Cited by 18 publications

(11 citation statements)

References 156 publications

(190 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Microbicides circumvent many of the immunological difficulties associated with HIV vaccine development and make topical formulations a more realistic goal, especially in the short term (27,28). The most promising strategy currently being pursued is the utilization of intravaginal delivery systems for microbicides (13,26,(29)(30)(31)(32)(33)(34).…”

Section: Methodsmentioning

confidence: 99%

A Review of Current Intravaginal Drug Delivery Approaches Employed for the Prophylaxis of HIV/AIDS and Prevention of Sexually Transmitted Infections

et al. 2008

View full text Add to dashboard Cite

Abstract. The objective of this review is to describe the current status of several intravaginal anti-HIV microbicidal delivery systems these delivery systems and microbicidal compounds in the context of their stage within clinical trials and their potential cervicovaginal defence successes. The global Human Immuno-Deficiency Virus (HIV) pandemic continues to spread at a rate of more than 15,000 new infections daily and sexually transmitted infections (STIs) can predispose people to acquiring HIV infection. Male-to-female transmission is eight times more likely to occur than female-to-male transmission due to the anatomical structure of the vagina as well as socio-economic factors and the disempowerment of women that renders them unable to refuse unsafe sexual practices in some communities. The increased incidence of HIV in women has identified the urgent need for efficacious and safe intravaginal delivery of anti-HIV agents that can be used and controlled by women. To meet this challenge, several intravaginal anti-HIV microbicidal delivery systems are in the process of been developed. The outcomes of three main categories are discussed in this review: namely, dual-function polymeric systems, non-polymeric systems and nanotechnology-based systems. These delivery systems include formulations that modify the genital environment (e.g. polyacrylic acid gels and lactobacillus gels), surfactants (e.g. sodium lauryl sulfate), polyanionic therapeutic polymers (e.g. carageenan and carbomer/lactic acid gels), proteins (e.g. cyanovirin-N, monoclonal antibodies and thromspondin-1 peptides), protease inhibitors and other molecules (e.g. dendrimer based-gels and the molecular condom). Intravaginal microbicide delivery systems are providing a new option for preventing the transmission of STIs and HIV.

show abstract

Section: Methodsmentioning

confidence: 99%

A Review of Current Intravaginal Drug Delivery Approaches Employed for the Prophylaxis of HIV/AIDS and Prevention of Sexually Transmitted Infections

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Since the first immunotherapeutic clinical trial for HIV/AIDS in 1983, various trials have been carried out and are still ongoing [90–93]. Unfortunately, despite the preclinical studies that showed enhanced immune responses, most of the clinical studies have consistently failed to provide clinical improvements for patients [90].…”

Section: Immunotherapy For Hiv/aidsmentioning

confidence: 99%

Emerging Nanotechnology Approaches for HIV/AIDS Treatment and Prevention

et al. 2010

View full text Add to dashboard Cite

Currently, there is no cure and no preventive vaccine for HIV/AIDS. Combination antiretroviral therapy has dramatically improved treatment, but it has to be taken for a lifetime, has major side effects and is ineffective in patients in whom the virus develops resistance. Nanotechnology is an emerging multidisciplinary field that is revolutionizing medicine in the 21st century. It has a vast potential to radically advance the treatment and prevention of HIV/AIDS. In this review, we discuss the challenges with the current treatment of the disease and shed light on the remarkable potential of nanotechnology to provide more effective treatment and prevention for HIV/AIDS by advancing antiretroviral therapy, gene therapy, immunotherapy, vaccinology and microbicides.

show abstract

“…Others were derived from the blood of HIV-infected patients. The clinical trials were recently reviewed [12]. Many of the trials were uncontrolled and enrolled relatively few patients.…”

Section: Outcome Measuresmentioning

confidence: 99%

Outcomes for therapeutic vaccines trials

Taiwo

Murphy²

2006

Current Opinion in HIV and AIDS

View full text Add to dashboard Cite

The design of therapeutic vaccine clinical trials has not kept pace with clinical standards for HIV care. Future trials should evaluate immunogenicity, but also investigate the impact of vaccine-induced immune responses on viral replication and the clinical course. Ideally, the studies should aim to demonstrate non-inferiority to uninterrupted, fully suppressive highly active antiretroviral therapy and define virological failure as a sustained plasma viral load greater than 50-400 copies/ml.

show abstract

Therapeutic AIDS Vaccines

Cited by 18 publications

References 156 publications

A Review of Current Intravaginal Drug Delivery Approaches Employed for the Prophylaxis of HIV/AIDS and Prevention of Sexually Transmitted Infections

A Review of Current Intravaginal Drug Delivery Approaches Employed for the Prophylaxis of HIV/AIDS and Prevention of Sexually Transmitted Infections

Emerging Nanotechnology Approaches for HIV/AIDS Treatment and Prevention

Outcomes for therapeutic vaccines trials

Contact Info

Product

Resources

About